Paxil CR Related Published Studies
Well-designed clinical trials related to Paxil CR (Paroxetine)
What if the Women's Health Initiative had used transdermal estradiol and oral
progesterone instead? [2014]
One-year long-term safety extension study of ospemifene for the treatment of
vulvar and vaginal atrophy in postmenopausal women with a uterus. [2013]
Paroxetine in the treatment of dysthymic disorder without co-morbidities: A
double-blind, placebo-controlled, flexible-dose study. [2013]
The paroxetine 352 bipolar trial: A study in medical ghostwriting. [2012]
Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials. [2011.11]
Combined Prolonged Exposure Therapy and Paroxetine for PTSD Related to the World Trade Center Attack: A Randomized Controlled Trial. [2011.09.09]
Neural correlates of antidepressant-related sexual dysfunction: a placebo-controlled FMRI study on healthy males under subchronic paroxetine and bupropion. [2011.08]
A randomized, controlled study comparing the effects of vestipitant or vestipitant and paroxetine combination in subjects with tinnitus. [2011.07]
Acupuncture versus paroxetine for the treatment of premature ejaculation: a randomized, placebo-controlled clinical trial. [2011.05]
Meta-regression analysis of paroxetine clinical trial data: does reporting scale matter? [2011.04]
Increased neural response to trauma scripts in posttraumatic stress disorder following paroxetine treatment: A pilot study. [2011.03.24]
Functional magnetic resonance imaging study on the effects of acute single administration of paroxetine on motivation-related brain activity. [2011.03]
Influence of metoprolol dosage release formulation on the pharmacokinetic drug interaction with paroxetine. [2011.03]
Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. [2011.02]
A pilot study of the efficacy and safety of paroxetine augmented with
risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese
patients with treatment-resistant major depression. [2011]
A randomized, controlled study comparing the effects of vestipitant or
vestipitant and paroxetine combination in subjects with tinnitus. [2011]
Meta-analysis of efficacy and treatment-emergent suicidality in adults by
psychiatric indication and age subgroup following initiation of paroxetine
therapy: a complete set of randomized placebo-controlled trials. [2011]
A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4
atypical neuroleptic drugs compared with haloperidol and placebo. [2011]
Specificity profile of paroxetine in major depressive disorder: meta-regression
of double-blind, randomized clinical trials. [2011]
Slow vs standard up-titration of paroxetine in the treatment of panic disorder: a prospective randomized trial. [2010.12]
The impact of paroxetine coadministration on stereospecific carvedilol pharmacokinetics. [2010.12]
Comparison of paroxetine and amitriptyline as adjunct to lithium maintenance therapy in bipolar depression: a reanalysis of a randomized, double-blind study. [2010.11]
A randomized, controlled trial of aerobic exercise in combination with paroxetine in the treatment of panic disorder. [2010.10]
[Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study]. [2010.10]
Heart-focused anxiety as a mediating variable in the treatment of noncardiac chest pain by cognitive-behavioral therapy and paroxetine. [2010.09]
Efficacy and safety of two treatment algorithms in bipolar depression consisting of a combination of lithium, lamotrigine or placebo and paroxetine. [2010.09]
Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a chinese population. [2010.08]
Two separate dose-dependent effects of paroxetine: mydriasis and inhibition of tramadol's O-demethylation via CYP2D6. [2010.07]
A randomized controlled study of paroxetine and cognitive-behavioural therapy for late-life panic disorder. [2010.07]
Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: escitalopram vs paroxetine. [2010.03]
Balneotherapy versus paroxetine in the treatment of generalized anxiety disorder. [2010.02]
A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). [2010.02]
Effects of paroxetine on emotional functioning and treatment awareness: a 4-week randomized placebo-controlled study in healthy clinicians. [2010.01]
Clinical features of patients with treatment-emergent suicidal behavior following initiation of paroxetine therapy. [2010.01]
Heart-focused anxiety as a mediating variable in the treatment of noncardiac
chest pain by cognitive-behavioral therapy and paroxetine. [2010]
Clinical features of patients with treatment-emergent suicidal behavior following
initiation of paroxetine therapy. [2010]
Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine. [2009.11.13]
Cognitive behavioral therapy versus paroxetine in the treatment of hypochondriasis: an 18-month naturalistic follow-up. [2009.09]
Redistribution of slow wave activity of sleep during pharmacological treatment of depression with paroxetine but not with nefazodone. [2009.09]
History of depressive and/or anxiety disorders as a predictor of treatment response: a post hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release in patients with fibromyalgia. [2009.08.31]
Investigating the efficacy of paroxetine in developmental stuttering. [2009.07]
The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. [2009.07]
Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. [2009.07]
A comparison of low-dose risperidone to paroxetine in the treatment of panic attacks: a randomized, single-blind study. [2009.05.26]
History of early abuse as a predictor of treatment response in patients with fibromyalgia: A post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. [2009.04.20]
Superiority of escitalopram to paroxetine in the treatment of depression. [2009.04]
Effects of acute alcohol intoxication and paroxetine on aggression in men. [2009.04]
Treatment of social anxiety with paroxetine: mediation of changes in anxiety and depression symptoms. [2009.03]
Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. [2009.03]
Childhood abuse and treatment response in patients with irritable bowel syndrome: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. [2009.02]
The Effects of Desvenlafaxine and Paroxetine on the Pharmacokinetics of the Cytochrome P450 2D6 Substrate Desipramine in Healthy Adults. [2009.02]
A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome. [2009.01]
Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial. [2009.01]
History of early abuse as a predictor of treatment response in patients with fibromyalgia: a post-hoc analysis of a 12-week, randomized, double-blind, placebo-controlled trial of paroxetine controlled release. [2009]
Low doses of controlled-release paroxetine in the treatment of late-life depression: A randomized, placebo-controlled trial. [2008.10.07]
Evidence Why Paroxetine Dose Escalation is Not Effective in Major Depressive Disorder: A Randomized Controlled Trial With Assessment of Serotonin Transporter Occupancy. [2008.10.01]
The effects of acute treatment with paroxetine, amitriptyline, and placebo on driving performance and cognitive function in healthy Japanese subjects: a double-blind crossover trial. [2008.07]
Luteal phase administration of paroxetine for the treatment of premenstrual dysphoric disorder: a randomized, double-blind, placebo-controlled trial in Canadian women. [2008.06]
Luteal Phase Administration of Paroxetine for the Treatment of Premenstrual Dysphoric Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial in Canadian Women. [2008.05.27]
Pharmacologic treatment of postpartum women with new-onset major depressive disorder: a randomized controlled trial with paroxetine. [2008.04]
Paroxetine CR augmentation for posttraumatic stress disorder refractory to prolonged exposure therapy. [2008.03]
Paroxetine with pindolol augmentation: A double-blind, randomized, placebo-controlled study in depressed in-patients. [2008.02]
Six-month paroxetine treatment of premenstrual dysphoric disorder: continuous versus intermittent treatment protocols. [2008.02]
Once-daily high-dose pindolol for paroxetine-refractory premature ejaculation: a double-blind, placebo-controlled and randomized study. [2008.02]
Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. [2008.01.29]
Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis. [2008.01]
Paroxetine-induced modulation of cortical activity supporting language representations of action. [2008.01]
Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder. [2008]
History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome: post hoc analysis from a placebo-controlled study. [2008]
Nocturnal urinary cortisol excretion over a randomized controlled trial with paroxetine vs. placebo combined with relaxation training or aerobic exercise in panic disorder. [2008]
Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment. [2008]
Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis. [2007.12]
Pharmacological interaction between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacokinetics. [2007.12]
A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. [2007.11]
A randomized, single-blind, comparison of venlafaxine with paroxetine in elderly patients suffering from resistant depression. [2007.11]
Paroxetine oral solution is bioequivalent to paroxetine tablets--advantages of the solution. [2007.11]
A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. [2007.10]
Pharmacological Interaction Between 3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) and Paroxetine: Pharmacological effects and pharmacokinetics. [2007.09.21]
Maintenance treatment for old-age depression preserves health-related quality of life: a randomized, controlled trial of paroxetine and interpersonal psychotherapy. [2007.09]
Clinical observation on treatment of depression by electro-acupuncture combined with Paroxetine. [2007.09]
Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. [2007.06.30]
A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. [2007.06.23]
[Effects of paroxetine with or without zolpidem on depression with insomnia: a multi-center randomized comparative study] [2007.06.19]
Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: a double-blind randomised placebo controlled 6-month trial. [2007.06.15]
Once-daily duloxetine 60 mg in the treatment of major depressive disorder: Multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil. [2007.06]
A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. [2007.05]
Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. [2007.05]
The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. [2007.04.05]
Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. [2007.04]
A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. [2007.02.08]
Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. [2007.02]
Cognitive behavior therapy and paroxetine in the treatment of hypochondriasis: a randomized controlled trial. [2007.01]
Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. [2007.01]
A validation of the 7.5% CO2 model of GAD using paroxetine and lorazepam in healthy volunteers. [2007.01]
Effects of three cytochrome P450 inhibitors, ketoconazole, fluconazole, and paroxetine, on the pharmacokinetics of lasofoxifene. [2007.01]
Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. [2007.01]
Determination of paroxetine in plasma by liquid chromatography coupled to tandem mass spectrometry for pharmacokinetic and bioequivalence studies. [2007]
Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). [2007]
The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. [2006.12.27]
Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. [2006.12]
Comparison of Hypericum extract WS 5570 and paroxetine in ongoing treatment after recovery from an episode of moderate to severe depression: results from a randomized multicenter study. [2006.11]
|
